Skip Ribbon Commands
Skip to main content
Clin Assoc Prof Linn Yeh Ching

Clin Assoc Prof Linn Yeh Ching


Senior Consultant

Singapore General Hospital

Specialty: Haematology

Sub-specialties: Haematopoietic Stem Cell & Cellular Therapy

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukemia (CML), Deep Vein Thrombosis, Deep Vein Thrombosis, essential thrombocythemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelofibrosis, Polycythemia Vera, Pulmonary Embolism, Thalassaemia.

Clinical Appointments

  • Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Senior Consultant SingHealth Duke-NUS Transplant Centre
  • Senior Consultant Haematology Singapore General HospitalSingapore General Hospital
  • Senior Consultant National Cancer Centre SingaporeNational Cancer Centre Singapore


Dr Linn Yeh Ching graduated from NUS in 1987 and obtained her MRCP (UK) in 1991.

She has been working in the Department of Haematology since then and is actively involved in clinical service, research and teaching. Her areas of interest are in haemopoietic stem cell transplantation and cellular immunotherapy.

She has published more than 40 research papers on the anti-leukemic activity and mechanisms of cytokine-induced killer (CIK) cells. She is principal investigator of clinical studies on use of CIK cells for leukemia post-autologous and allogeneic haemopoietic stem cell transplantation in adjuvant and salvage setting, with fundings from National Medical Research Council and SingHealth Research Funds.

She also has a keen interest Traditional Chinese Medicine from the perspectives of evidence – based medicine and its safe use with Western Medicine.


  • ​MBBS/1987, National University of Singapore  
  • MRCP(UK)/1991, Royal College of Physician, UK

Professional Appointments and Committee Memberships

  • Clinical Senior Lecturer, Yong Loo Lin School of Medicine, National University of Singapore
  • Adjunct Associate Professor, Duke-NUS Medical School, Singapore


Research Interests

  • haemopoietic stem cell transplantation
  • cellular immunotherapy


  • Pwint K-SW, Chen Y, Diong CP, Goh Y-T, Grant D, Ho A, et al. Mobilization kinetics of peripheral blood stem cells with rescue plerixafor - real-world experience from a single center. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 1740–3.
  • Leung W, Soh TG, Linn YC, Low JG-H, Loh J, Chan M, et al. Rapid production of clinical-grade SARS-CoV-2 specific T cells. Adv cell gene Ther. 2020 Jul;e101.
  • Ho LP, Teo Bryan YW, Linn YC, Tan PH, Jabed I, Toh HC, et al. Unifying framework for acute resolution, malignancy and autoimmunity. Vol. 91, Scandinavian journal of immunology. England; 2020. p. e12869.
  • Quek J, Lee JJ, Lim FL, Diong C, Goh YT, Gopalakrishnan S, et al. Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. Transfusion. 2019 Jan;59(1):335–9.
  • Luah YH, Sundar Raj K, Koh MBC, Linn YC. A novel simplified method of generating cytomegalovirus-specific cytokine-induced killer cells of high specificity and superior potency with GMP compliance. Clin Immunol. 2019 Aug;205:83–92.
  • Teo YWB, Linn YC, Goh YT, Li S, Ho LP. Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (Simulated Infective Protocol). Immunobiology. 2019 Jul;224(4):526–31.
  • Pock HL, Wei Bryan TY, Hoon TP, Iqbal J, Ching LY, Tee GY, et al. Standing in the GAP: To formulate a novel radioimmunotherapy regime to improve the long-term outcome in breast cancer. Immunotherapy. 2018 Feb;10(4):255–63.
  • Cao L, Koh LP, Linn YC. Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib. Vol. 59, Leukemia & lymphoma. United States; 2018. p. 2500–2.
  • Yeap WH, Wong KL, Shimasaki N, Teo ECY, Quek JKS, Yong HX, et al. Corrigendum: CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep. 2017 Apr;7:46202.
  • Fung FY, Wong WH, Ang SK, Koh HL, Kun MC, Lee LH, et al. A randomized, double-blind, placebo- controlled study on the anti-haemostatic effects of Curcuma longa, Angelica sinensis and Panax ginseng. Phytomedicine. 2017 Aug;32:88–96.
  • Mya HT, Linn YC, Lim LC, Ng HJ. Chronic NK lymphocytosis identified by a distinct immunophenotypic pattern. Vol. 105, International journal of hematology. Japan; 2017. p. 3–4.
  • Wang L, Allen J, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center: Predictive value of the immunodeficiency scoring index. Transpl Infect Dis. 2017 Jun;19(3).
  • Zhou W, Sultana R, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. Long-term renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis of risk factors in an Asian patient population. Clin Transplant. 2017 Apr;31(4).
  • Her Z, Yong KSM, Paramasivam K, Tan WWS, Chan XY, Tan SY, et al. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia. J Hematol Oncol. 2017 Oct;10(1):162.
  • Fung FY, Linn YC. Steroids in traditional Chinese medicine: what is the evidence? Singapore Med J. 2017 Mar;58(3):115–20.
  • Yeap WH, Wong KL, Shimasaki N, Teo ECY, Quek JKS, Yong HX, et al. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep. 2016 Sep;6:34310.
  • Phipps C, Ho AY, Linn YC, Gopalakrishnan S, Ang AL, Lee JJ, et al. Thirty Years of Bone Marrow Transplantation in the Singapore General Hospital. Ann Acad Med Singapore. 2016 Jul;45(7):315–7.
  • Ghosh A, Tan TT, Linn YC, Gopalakrishnan S, Goh YT, Hwang W, et al. What We Learned From Plasma BK-Virus Monitoring in Allogeneic Hematopoietic Transplant Recipients. Vol. 100, Transplantation. United States; 2016. p. e17-8.
  • Suck G, Linn YC, Tonn T. Natural Killer Cells for Therapy of Leukemia. Transfus Med hemotherapy Off Organ der Dtsch Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2016 Mar;43(2):89–95.
  • Poh SL, Linn YC. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. Cancer Immunol Immunother. 2016 May;65(5):525–36.
  • Shen M, Linn Y-C, Ren E-C. KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients. Immunogenetics. 2016 Feb;68(2):133–44.
  • Chan W-C, Linn Y-C. A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role. Cytotechnology. 2016 Aug;68(4):735–48. 
  • Ong S-Y, Ng HY, Surendran S, Linn YC, Chen Y, Goh YT, et al. Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Vol. 169, British journal of haematology. England; 2015. p. 754–6.
  • Ong S-Y, Truong H-T-T, Diong CP, Linn Y-C, Ho AY-L, Goh Y-T, et al. Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation. BMC Hematol. 2015;15:8.
  • Ma L, Hao S, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients. Ann Hematol. 2015 May;94(5):761–9.
  • Ma L, Hao S, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of Southeast Asian patients. Leuk Lymphoma. 2015 May;56(5):1362–9.
  • Fung FY, Linn YC. Developing traditional chinese medicine in the era of evidence-based medicine:  current evidences and challenges. Evid Based Complement Alternat Med. 2015;2015:425037.
  • Tay LK, Linn YC, Pang SM, Thirumoorthy T. Plasmapheresis in refractory pemphigus vulgaris: revisiting an old treatment modality used in synchrony with pulse cyclophosphamide. Vol. 95, Cutis. United States; 2015. p. E17-9.
  • Cheng K, Wong SC, Linn YC, Ho LP, Chng WJ, Schwarz H. CD137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells. Br J Haematol. 2014 Apr;165(1):134–44.
  • Ho X, Fook-Chong S, Linn Y-C. Natural killer cell receptor repertoire is comparable amongst newly diagnosed acute myeloid leukemia of different French-American-British subtypes, risk categories and chemosensitivities. Leuk Lymphoma. 2014 Feb;55(2):342–8.
  • Ho LP, Yit PS, Ng LH, Linn YC, Zhao Y, Sun L, et al. The road to memory: an early rest for the long journey. J Immunol. 2013 Dec;191(11):5603–14.
  • Tan LHC, Tan SY, Tang T, Lim ST, Tan D, Lim LC, et al. Relationship between atypical T- and B-cell size predicts survival in peripheral T-cell lymphomas with large B-cells. Pathology. 2013 Jan;45(1):28–37.
  • Linn Y-C, Yong H-X, Niam M, Lim T-J, Chu S, Choong A, et al. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012 Aug;14(7):851–9.
  • Wu F, Heng KK, Salleh RB, Soh TG, Lee JJ, Mah J, et al. Comparing peripheral blood stem cell collection using the COBE Spectra, Haemonetics MCS+, and Baxter Amicus. Transfus Apher Sci Off J World Apher  Assoc  Off J Eur Soc Haemapheresis. 2012 Dec;47(3):345–50.
  • Yong HX, Linn YC, Ong KH, Tan D. Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia. Vol. 36, Leukemia research. England; 2012. p. e163-5.
  • Mohan BP, How G, Loh Y, Linn Y. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia. Vol. 157, British journal of haematology. England; 2012. p. 131–2.
  • Linn Y, Lu J, Lim L-C, Sun H, Sun J, Zhou Y, et al. Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex  phellodendri in chronic haematological diseases. Phytother Res. 2012 May;26(5):682–6.
  • Linn Y-C, Lu J, Lim L-C, Sun H, Sun J, Zhou Y. Traditional Chinese herbal medicine in the supportive management of patients with chronic cytopaenic marrow diseases -- a phase I/II clinical study. Complement Ther Clin Pract. 2011 Aug;17(3):152–6.
  • Niam M, Linn Y-C, Fook Chong S, Lim T-J, Chu S, Choong A, et al. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol. 2011 Sep;39(9):897-903.e1.
  • Suck G, Oei VYS, Linn YC, Ho SH, Chu S, Choong A, et al. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp Hematol. 2011 Sep;39(9):904–14.
  • Hwang WYK, Koh LP, Lim S-T, Linn YC, Loh YS, Koh MBC, et al. Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphoma. Vol. 52, Leukemia & lymphoma. United States; 2011. p. 1382–6.
  • Kei PL, Kok TY, Linn YC, Padhy AK. Butterfly lesion of the corpus callosum: an unusual case of extramedullary myeloid sarcoma (granulocytic sarcoma). Clin Nucl Med. 2011 May;36(5):365–6.
  • Phang BH, Chua HW, Li H, Linn YC, Sabapathy K. Characterization of novel and uncharacterized p53 SNPs in the Chinese population--intron 2 SNP co-segregates with the common codon 72 polymorphism. PLoS One. 2011 Jan;6(1):e15320.
  • Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010;2010:435745.
  • Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer. 2008 Mar;44(5):760–6.
  • Koh L-P, Chen C-S, Tai B-C, Hwang WYK, Tan L-K, Ng H-Y, et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biol blood marrow Transplant J Am Soc Blood Marrow Transplant. 2007 Jul;13(7):790–805.
  • Hwang WYK, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol blood marrow Transplant J Am Soc Blood Marrow Transplant. 2007 Apr;13(4):444–53.
  • Loh YSM, Koh LP, Tai BC, Hwang WYK, Linn YC, Goh YT, et al. Long-term follow-up of Asian patients younger than 46 years with acute myeloid  leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leuk Lymphoma. 2007 Jan;48(1):72–9.
  • Chuah C, Lim TH, Lim AST, Tien SL, Lim CH, Soong R, et al. Dasatinib induces a response in malignant thymoma. Vol. 24, Journal of clinical oncology: official journal of the American Society of Clinical Oncology. United States; 2006. p. e56-8.
  • Loh SMY, Ratnagopal P, Tan HCP, Goh YT, Koh BCM, Koh LP, et al. Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning. Vol. 83, International journal of hematology. Japan; 2006. p. 368–9.
  • Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol. 2005 Jun;33(6):671–81.

Research Trials